Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer.

Erik S KnudsenVishnu KumarasamySejin ChungAmanda RuizParis VailStephanie TzetzoJin WuRam NambiarJared SivinskiShailender S ChauhanMukund SeshadriScott I AbramsJianmin WangAgnieszka K Witkiewicz

Published in: Gut (2020)

Together, these data indicate that there are canonical and non-canonical features of CDK4/6 and MEK inhibition that impact on the tumour and immune microenvironment. This combination-targeted treatment can promote robust tumour control in combination with immune checkpoint inhibitor therapy.

Keyphrases

stem cells
cancer therapy
cell cycle
machine learning
combination therapy
drug delivery
signaling pathway
artificial intelligence
replacement therapy